However, SSTR2 expression profiles in tumor cells and their association with the therapeutic efficacy of SSAs remains virtually unknown in gastrointestinal NETs (GI-NETs). This evidence concerns the gene SSTR2 and digestive system neuroendocrine tumor, grade 1/2.